Single Use Bioreactors Market Size, Share, Industry Trends and Forecast to 2030

Market Size & CAGR of Single Use Bioreactors Market in 2021

The global single-use bioreactors market is projected to experience a substantial growth rate in 2021, with a Compound Annual Growth Rate (CAGR) of around 8.5%. This growth is expected to drive the market size to approximately USD 1.2 billion by the end of the year. The increasing adoption of single-use bioreactors in the biopharmaceutical industry is a key factor contributing to this growth. Single-use bioreactors offer advantages such as reduced operational costs, faster turnaround times, and enhanced flexibility in manufacturing processes, making them a preferred choice for many biopharmaceutical companies.

COVID-19 Impact on the Single Use Bioreactors Market

The COVID-19 pandemic has had a mixed impact on the single-use bioreactors market. On one hand, the increased demand for biopharmaceuticals and vaccines to combat the virus has led to a surge in the use of single-use bioreactors for production. This has resulted in a significant boost in market growth for single-use bioreactors. However, the disruptions in the global supply chain and manufacturing processes caused by the pandemic have also posed challenges for the market. Delays in the delivery of raw materials and components for single-use bioreactors have impacted production schedules and led to supply chain bottlenecks.

Single Use Bioreactors Dynamics

Single-use bioreactors have been gaining significant traction in the biopharmaceutical industry due to their numerous advantages over traditional stainless steel bioreactors. These advantages include lower upfront costs, reduced risk of contamination, ease of scalability, and faster setup times. The growing trend towards personalized medicine and the increasing demand for biopharmaceutical products are driving the adoption of single-use bioreactors. Additionally, advancements in technology and the development of novel biologics are further fueling market growth.

Segments and Related Analysis

The single-use bioreactors market can be segmented based on type, application, and end-user. By type, the market is divided into stirred-tank single-use bioreactors, wave-induced single-use bioreactors, and other types. Based on application, the market includes monoclonal antibody production, vaccine production, cell therapy, and others. End-users of single-use bioreactors are pharmaceutical companies, biotechnology companies, contract manufacturing organizations, and research institutes. The growing utilization of single-use bioreactors across various applications and end-user industries is driving market growth.

By Region Analysis

The single-use bioreactors market is geographically segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. North America currently holds the largest market share due to the presence of a well-established biopharmaceutical industry and increasing investments in R&D. Europe is also a significant market for single-use bioreactors, driven by the growing demand for biopharmaceuticals. The Asia Pacific region is anticipated to witness rapid growth in the market, supported by the expanding biotechnology sector and increasing government initiatives to promote biopharmaceutical manufacturing.

Key Market Players and Competitive Landscape

Some of the key players in the single-use bioreactors market include Thermo Fisher Scientific Inc., Merck KGaA, GE Healthcare, Sartorius AG, Pall Corporation, Danaher Corporation, Applikon Biotechnology, Eppendorf AG, Pierre Guérin, and Cellexus Ltd. These companies are focusing on product development, strategic partnerships, and acquisitions to strengthen their market position and expand their product offerings. The competitive landscape of the single-use bioreactors market is characterized by intense competition and innovative product launches.

Recent Happenings in the Single Use Bioreactors Market

- In January 2021, Thermo Fisher Scientific announced the launch of its new single-use bioreactor system, designed to meet the growing demand for flexible and scalable biopharmaceutical manufacturing solutions. - In March 2021, Merck KGaA acquired AmpTec, a leading supplier of RNA and mRNA synthesis technologies, to enhance its capabilities in the nucleic acid-based therapeutics market. - In August 2021, GE Healthcare introduced a new range of single-use bioreactors with enhanced features for cell and gene therapy applications. - In December 2021, Sartorius AG collaborated with a biopharmaceutical company to develop and optimize single-use bioreactor systems for the production of monoclonal antibodies.